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Abstract: Background. The polysaccharide fucoidan is widely investigated as an anti-cancer agent.
Here, we tested the effect of fucoidan on uveal melanoma cell lines. Methods. The effect of
100 µM fucoidan was investigated on five cell lines (92.1, Mel270 OMM1, OMM2.3, OMM2.5) and of
1 µg/mL–1 mg/mL fucoidan in two cell lines (OMM1, OMM2.3). Cell proliferation and viability were
investigated with a WST-1 assay, migration in a wound healing (scratch) assay. Vascular Endothelial
Growth Factor (VEGF) was measured in ELISA. Angiogenesis was evaluated in co-cultures with
endothelial cells. Cell toxicity was induced by hydrogen-peroxide. Protein expression (Akt, ERK1/2,
Bcl-2, Bax) was investigated in Western blot. Results. Fucoidan increased proliferation in two and
reduced it in one cell line. Migration was reduced in three cell lines. The effect of fucoidan on VEGF
was cell type and concentration dependent. In endothelial co-culture with 92.1, fucoidan significantly
increased tubular structures. Moreover, fucoidan significantly protected all tested uveal melanoma
cell lines from hydrogen-peroxide induced cell death. Under oxidative stress, fucoidan did not
alter the expression of Bcl-2, Bax or ERK1/2, while inducing Akt expression in 92.1 cells but not
in any other cell line. Conclusion. Fucoidan did not show anti-tumorigenic effects but displayed
protective and pro-angiogenic properties, rendering fucoidan unsuitable as a potential new drug for
the treatment of uveal melanoma.
Keywords: fucoidan; uveal melanoma; VEGF; angiogenesis; oxidative stress
1. Introduction
Uveal melanoma (UM) is the most common primary tumor of the adult eye with an incidence of
4–8 per million in Western countries [1]. It arises from melanocytes of the uvea, the tissue between the
inner retina and the outer scleral layer of the posterior eye, including the iris, ciliary body and choroid.
Most UM arise from the choroid, which provides blood supply and maintenance for the photoreceptors
of the retina. The disease generally occurs in the 6th decade of life and primarily affects fair-skinned
people of Caucasian descent [2]. Treatment options for UM depend on the tumor size and patient
choice, but include transpupillary thermotherapy, radiation therapy (including plaque brachytherapy,
proton beam- and gamma-knife radiotherapy), local tumor resection and enucleation [2]. Radiation
therapy is conducted with good success for medium sized tumors, however, it may result in profound
vision loss due to side effects [3]. Metastases develop in up to 50% of UM patients, primarily affecting
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the liver. The prognosis of these patients is poor, as the current treatment options for metastatic UM
are very limited [1,4]. New treatment options for this disease are currently of great interest and are an
important activity of numerous basic and clinical research teams.
A promising new approach in the treatment of cancer is the use of fucoidan, a sulfated
polysaccharide, obtained from the cell-wall matrix of brown algae. Fucoidan contains high amounts
of L-fucose, but has a highly complex structure and may differ substantially depending on different
species, regional origin and even mode of extraction [5]. Fucoidan has been reported in several
studies to have anti-tumorigenic properties, e.g., it has been shown to be anti-proliferative and/or
pro-apoptotic on several kind of tumors cells, such as colon cancer [6], hepatoma [7], urinary bladder
cancer cells [8], breast cancer [9], melanoma cells [10] or prostate cancer cells [11]. Fucoidan has also
shown anti-angiogenic properties [6,12,13] and is discussed as a promising anti-cancer agent [14].
Therefore, fucoidan might be an interesting new therapeutic compound for the treatment of UM.
Important parameters in tumor progression are proliferation, migration and angiogenic
potential [5]. We tested the effect of fucoidan on these parameters in five different UM cell lines.
One of the factors that have been discussed to be involved in the pathogenesis of UM is Vascular
Endothelial Growth Factor (VEGF). VEGF has been reported in UM, ocular fluid of UM patients
and UM cell lines [15–17]. A meta-analysis showed that VEGF expression in patients with UM was
significantly higher compared to controls [18]. Moreover, VEGF has been elevated in patients with
metastatic UM [17], and has been proposed to be a marker for high risk patients [18]. Fucoidan
has been reported to reduce VEGF expression in breast cancer cells [9] and in Lewis tumor bearing
mice [19]. Therefore, we investigated the effect of fucoidan on VEGF secretion by UM cells.
Oxidative stress is an important factor in tumor pathology and metastasis [20,21] and is utilized
by therapeutic compounds to destroy the tumor tissue [22]. In primary UM, the tumor is treated
with ionizing radiation, which induces cell death via oxidative stress-mediated killing of tumor
cells [3,23]. Therefore, we also tested the effect of fucoidan on UM cells stressed with Hydrogen
peroxide (H2O2). Fucoidan has been shown to exert its anti-tumor functions via ERK1/2, Akt [6,11,12],
Bcl-2 and Bax [8,9,24,25]; all these proteins have also been implicated in the pathogenesis of UM [26–31].
Therefore, we also assessed how fucoidan affects the expression of these proteins under oxidative stress.
2. Results
2.1. Proliferation
Fucoidan had a cell specific effect on cell proliferation. In 92.1 cells, fucoidan induced a significant
increase in cell number one day (p < 0.05), two days (p < 0.01) and three days (p < 0.05) after incubation,
while in Mel270 cells, fucoidan reduced proliferation after two and three days (both p < 0.05). OMM1
and OMM2.3 were not affected by fucoidan, while in OMM2.5 cells, fucoidan increased cell number
significantly after one day of incubation (p < 0.001) (Figure 1). In addition, for OMM1 and OMM2.3,
different concentrations (1 µg/mL, 10 µg/mL, 100 µg/mL, 1 mg/mL) after one day of incubation
were tested. Fucoidan did not show any significant effect in either cell line or in either concentration
(Figure 2).
2.2. Wound Healing/Migration
Fucoidan induced a significant decrease in wound healing ability in 92.1 cells, OMM2.3, and
OMM2.5 cells (all p < 0.05). No significant effect was seen on Mel270 and OMM1 cells (Figure 3).
2.3. VEGF Secretion
We have previously shown that all tested UM cell lines secrete VEGF [32] and that this batch of
fucoidan reduces VEGF in retinal pigment epithelial cells in the tested concentration [33]. Fucoidan
(100 µg/mL) did not inhibit VEGF secretion in any of the UM cell lines when incubated for up to
three days (Figure 4). However, these results are dose and cell-line dependent. In a separate set of
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experiments, we investigated different concentrations of fucoidan (1 µg/mL, 10 µg/mL, 100 µg/mL,
1 mg/mL) in OMM1 and OMM2.3 cells after treatment for one day. While for OMM2.3 cells, a slight but
significant induction of VEGF could be found at 10 and 100 µg/mL, fucoidan at 1 mg/mL significantly








with  fucoidan  (100 μg/mL)  for one,  two, and  three days  in  (A) 92.1;  (B) Mel 270;  (C) OMM1;  (D) 







fucoidan. No  significant effect on proliferation was  found. Statistical  significance was evaluated with 
student’s t‐test. 
Figure 1. Proliferation (time line). Proliferation of uveal melanoma cells was tested after incubation with
fucoidan (100 µg/mL) for one, two, and three days in (A) 92.1; (B) Mel 270; (C) OMM1; (D) OMM2.3
and (E) OMM2.5 cells. Fucoidan exhibited a cell specific effect with an acceleration of proliferation
in 92.1 and OMM2.5 cells, but a decrease in Mel270 cells. Statistical significance was evaluated with
student’s t-test. + p < 0.05 compared to control, ++ p < 0.01 compared to control, +++ p < 0.001 compared
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fucoidan. No  significant effect on proliferation was  found. Statistical  significance was evaluated with 
student’s t‐test. 
Figure 2. Proliferation (concentration). Proliferation of uveal melanoma cell lines (A) OMM1 and
(B) OMM2.3 was tested after one day of treatment with 1 µg/mL, 10 µg/mL, 100 µg/mL or 1000 µg/mL
fucoidan. No significant effect on proliferation was found. Statistical significance was evaluated with
student’s t-test.
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Figure 3. Wound healing. Wound healing ability f l a ce ls was tested after incubation
with fucoidan (100 µg/mL) for one day in 92.1, Mel 270, OMM1, O M2.3 and OMM2.5 cells. Fucoidan
significantly decreased wound healing in 92.1, OMM2.3 and 5 cells. Statistical significance was
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Figure 4. Vascular Endo helial Growth F ctor (VEGF) secretion (time line). Influence of fucoidan
(100 µg/mL) n VEGF secretion by uveal melanoma cell lines. Treatment with fucoidan for up to three
days did not show any significant influence on the secretion of VEGF i any of the cell lines tested
(A) 92.1; (B) Mel270; (C) OMM1; (D) OMM2.3; (E) OMM2.5. The secretion of VEGF was determined in
VEGF-ELISA. Statistical significance was evaluated with student’s t-test. Co: control.






with  fucoidan displayed  a dose‐  and  cell‐dependent  effect with  significant  reduction of VEGF  in 
OMM1 (100 μg/mL, 1 mg/mL) and a slight but significant induction in OMM2.3 cells (10 μg/mL, 100 











were  increased by  fucoidan. Total  coverage with endothelial  cells, however, was not  influenced.  In 
co‐cultures with endothelial cells and OMM2.3 cell  line,  fucoidan displayed no effect  (B). Statistical 
significance was evaluated with student’s t‐test. ++ p < 0.01 compared to control. Co = control. 
2.5. Protection 
We  have  previously  shown  that  the  UM  cell  lines  have  a  different  susceptibility  towards 
H2O2‐induced cell toxicity [32]. In all cell  lines tested, fucoidan exerted a significant protection on 
Figure 5. VEGF secretion (concentration). Influence of different concentrations of fucoidan (1 µg/mL–
1 mg/mL) on VEGF secretion in (A) OMM1 and (B) OMM2.3 uveal melanoma cell lines. Treatment
with fucoidan displayed a dose- and cell-dependent effect with significant reduction of VEGF in OMM1
(100 µg/mL, 1 mg/mL) and a slight but significant induction in OMM2.3 cells (10 µg/mL, 100 µg/mL).
The secretion of VEGF was determined in VEGF-ELISA. Statistical significance was evaluated with
student’s t-test. + p < 0.05, ++ p < 0.01, +++ p < 0.001. Co: control.
2.4. Angiogenesis
Fucoidan induced an elevation of the tubular area in a co-culture of endothelial cells with 92.1 cells
(p < 0.01). Similarly, fucoidan increased tubular length (p < 0.01). Fucoidan did not, however, influence
the total area of endothelial coverage in these co-cultures. No effect was seen in co-cultures of
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were  increased by  fucoidan. Total  coverage with endothelial  cells, however, was not  influenced.  In 
co‐cultures with endothelial cells and OMM2.3 cell  line,  fucoidan displayed no effect  (B). Statistical 
significance was evaluated with student’s t‐test. ++ p < 0.01 compared to control. Co = control. 
2.5. Protection 
We  have  previously  shown  that  the  UM  cell  lines  have  a  different  susceptibility  towards 
H2O2‐induced cell toxicity [32]. In all cell  lines tested, fucoidan exerted a significant protection on 
Figure 6. Tubular structures in endothelial–uveal melanoma cell line co-culture. Uveal melanoma cell
line 92.1 and OMM2.3 were co-cultured with outgrowth endothelial cells and subjected to 100 µg/mL
fucoidan. In co-cultures with endothelial cells and 92.1 cell line (A), tubular area and tubular length
were increased by fucoidan. Total coverage with endothelial cells, however, was not influenced.
In co-cultures with endothelial cells and OMM2.3 cell line, fucoidan displayed no effect (B). Statistical
significance was evaluated with student’s t-test. ++ p < 0.01 compared to control. Co = control.
2.5. Protection
We have previously shown that the UM cell lines have a different susceptibility towards
H2O2-induced cell toxicity [32]. In all cell lines tested, fucoidan exerted a significant protection
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on UM cell lines under oxidative stress. (92.1, 250 µM H2O2, p < 0.01; Mel270, 500 µM H2O2, p < 0.01;













significant  protection  in  all  cell  lines  tested.  Statistical  significance was  evaluated with  student’s 
t‐test. + p < 0.05, ++ p < 0.01, +++ p < 0.001. 
2.6. Protein Expression 
Under  oxidative  stress  conditions  fucoidan  did  not  show  any  influence  on  Bcl‐2  or  Bax 
expression  in  any  of  the  cell  lines  (Figure  8).  In  92.1  cell  lines,  fucoidan  induced  a  significant 
induction  of  Akt  expression  compared  to  cells  treated  with  H2O2  alone,  while  it  showed  no 
significant effect on  the other cell  lines  (Figure 9). Considering ERK1/2, no statistically significant 








Figure 7. Cell viability of uveal melanoma cell lines under oxidative stress. Uveal melanoma cell lines
92.1, Mel270, OMM1, OMM2.3, and OMM2.5 were subjected to 250 µM (92.1), 500 µM, (Mel270 and
OMM1) or 1000 µM (OMM2.3 and OMM2.5) H2O2. The toxicity of these concentrations of H2O2 in the
respective cell line has been shown previously [32]. The ability of 100 µg/mL fucoidan to protect cell
viability after H2O2 treatment was detect d in WST assay. All tested substances xhibited statistically
significant protection in all cell lines tested. Statistical significance was evaluated with student’s t-test.
+ p < 0.05, ++ p < 0.01, +++ p < 0.001.
2.6. Protein Express on
Under oxidative stress conditions fucoidan did not show any influence on Bcl-2 or Bax expression
in any of the cell lines (Figure 8). In 92.1 cell lines, fucoidan induced a significant induction of Akt
expression compared to cells treated with H2O2 alone, while it showed no significant effect on the other
cell lines (Figure 9). Considering ERK1/2, no statistically significant change in ERK1/2 expression or
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i r . r si of Bcl-2 and Bax. Uveal melanoma cell lines (A) 92.1; (B) Mel270; (C) OMM1;
(D) OMM2.3; (E) OMM2.5 were subjected to (A) 250 µM; (B,C) 500 µM or (D,E) 1000 µM H2O2.
The effect of 100 µg/mL fucoidan on the expression of Bcl-2 a d Bax was investigated in Western
l t. Exa le blots (compound) and densitometric evaluatio s are shown. Statistical significance was
evalua e with s udent’s t-test.










Figure 9. Expression of Akt. Uveal melanoma cell lines 92.1, Mel270, OMM1, OMM2.3 and OMM2.5
were subjected to 250 µM (92.1), 500 µM (Mel270 and OMM1) or 1000 µM (OMM2.3 and OMM2.5)
H2O2. The effect 100 µg/mL fucoidan on the expression of Akt was investigated in Western blot.
Densitometric evaluations (A) and example blots (compound) (B) are shown. Statistical significance
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Figure  10.  Expression  and  phosphorylation  of  ERK1/2. Uveal melanoma  cell  lines  92.1, Mel270, 
OMM1, OMM2.3 and OMM2.5 were subjected to 250 μM (92.1), 500 μM (Mel270 and OMM1) or 1000 
μM  (OMM2.3  and  OMM2.5)  H2O2.  The  effect  of  100  μg/mL  fucoidan  on  the  expression  and 
phosphorylation of ERK1/2 was investigated in Western blot. Densitometric evaluation of (A) ERK 
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protein expression. 





no  effect  on  proliferation was  seen  at  either  time  point  or  contranction.  The  effect,  therefore,  is 
clearly  cell  type  specific.  Moreover,  the  pro‐proliferative  effect  on  two  cell  lines  would  be  a 
worrisome result if fucoidan were to be used in UM patients. 
Fucoidan decreased its wound healing ability in three (92.1; OMM2.3; OMM2.5) out of five UM 
cell  lines. This  indicates  that  fucoidan  interferes with migration  in  these  cell  lines,  especially  as 
wound healing assay measure both proliferation and migration, and we found fucoidan to induce 
proliferation in 92.1 and OMM2.5 cells. Fucoidan has been shown to inhibit migration e.g., in colon, 




epithelial  (RPE) cells  [33], where we could  find a significant reduction of detectable VEGF at  this 
concentration using  the same batch of  fucoidan A similar reductive effect of VEGF expression by 
fucoidan has been  shown  for breast  cancer  cells  [9]. Therefore,  the  effect of  fucoidan  is not only 
determined by  the molecular  structure of  the  fucoidan  [5], but also by  the  target cells. As higher 




elucidated  to date, but  it has been shown  that  fucoidan can  inhibit  the activation of VEGFR‐2 by 
preventing  the binding of VEGF165  to  its  receptor  [39]. We have previously shown  that VEGF  is 
autoregulated via the VEGFR‐2 in RPE cells [40], and so we hypothesized that the downregulation of 
VEGF was mediated by interfering with the autoregulatory pathway. The cell dependent effect of 
fucoidan  concerning  VEGF  in  the  UM  cells  may  therefore  be  related  to  the  presence  of  an 
autoregulatory pathway of VEGF expression in the tested melanoma cells. 
In addition, in our angiogenesis assay, fucoidan induced the outgrowth of tubular structures, 
both  in  length  and  area,  in  92.1  cells.  Even  though  the  general  interaction  between  92.1  and 
Figure 10. Expression and phosphorylation of ERK1/2. Uveal melanoma cell lines 92.1, Mel270,
OMM1, OMM2.3 and OMM2.5 were subjected to 250 µM (92.1), 500 µM (Mel270 and OMM1) or
1000 µM (OMM2.3 and OMM2.5) H2O2. The effect of 100 µg/mL fucoidan on the expression and
phosphorylation of ERK1/2 was investigated in Western blot. Densitometric evaluation of (A) ERK
and (B) pERK blots are shown for the 42 kDa isoform. (C) Example blots (compound). Statistical
significance was evaluated with student’s t-test.
3. Discussion
Fucoidan has been shown to display a vari ty f anti-tumor effects on several types umors or
canc r cell lines. Here, we investigat d its effect on UM, a primary aligna t neoplasm of he eye. We
invest gated classical parameters, such as proliferation, migratio , VEGF secretion and angioge esis
and additionally investigated the effect of fucoidan on H2O2-induced cell death and protein expression.
Anti-proliferative activity of fucoi a as ee s o n for several cancer cell types, such as
bronchopulmonary carcinoma [34], cutaneous elano a cells [10,35], bladder cancer cells [8], breast
cancer cells [9], or B-cell lymphoma [36]. In our study, fucoidan reduced proliferation in one cell line
(Mel 270), but, surprisingly, it induced proliferation in two cell lines (92.1 and OMM2.5). In OMM1
and OMM2.3 cells, both time line (100 µg/mL) and concentration (1 µg/mL–1 mg/mL) was tested
and no effect on proliferation was seen at either time point or contranction. The effect, therefore, is
clearly cell type specific. Moreover, the pro-proliferative effect on two cell lines would be a worrisome
result if fucoidan were to be used in UM patients.
Fucoidan decreased its wound healing ability in three (92.1; OMM2.3; OMM2.5) out of five UM
cell lines. This indicates that fucoidan interferes with migration in these cell lines, especially as wound
healing assay measure both proliferation and migration, and we found fucoidan to induce proliferation
in 92.1 and OMM2.5 cells. Fucoidan has been shown to inhibit migration e.g., in colon, lung or bladder
cancer cells [6,37,38]. Again, the effect is cell-type dependent, and no general anti-migratory effect of
fucoidan could be shown here.
When w tested the ability of fucoidan to reduce the avail bility of VEGF, no reduction of VEGF
could b seen at a oncentration of 100 µg/mL. Thi is n cont ast to ur findings in retinal pigment
epithelial (RPE) cells [33], where we could find a sign ficant reduction of detectable VEGF at this
concentr tion using t e same batch of fu oidan A simila reductive effect o VEGF expression by
fucoidan has een shown for breast cancer cells [9]. Therefore, the effect of fucoidan i not only
determined by the molecular structure of the fucoidan [5], but also by the target cells. As higher
concentrations of fucoidan did reduce VEGF in OMM1 cells, it is possible that the concentrations
chosen in this experiment were too low to exert an effect. However, even in higher concentrations, the
effect was cell type dependent, as OMM2.3 did not show any reduction of VEGF in any of the fucoidan
concentrations tested. The pathways of fucoidan-mediated VEGF reduction have not been elucidated
to date, but it has been shown that fucoidan can inhibit the activation of VEGFR-2 by preventing the
binding of VEGF165 to its receptor [39]. We have previously shown that VEGF is autoregulated via the
VEGFR-2 in RPE cells [40], and so we hypothesized that the downregulation of VEGF was mediated
by interfering with the autoregulatory pathway. The cell dependent effect of fucoidan concerning
VEGF in the UM cells may therefore be related to the presence of an autoregulatory pathway of VEGF
expression in the tested melanoma cells.
In addition, in our angiogenesis assay, fucoidan induced the outgrowth of tubular structures, both
in length and area, in 92.1 cells. Even though the general interaction between 92.1 and endothelial cells
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were low, this result may indicate that fucoidan may facilitate angiogenesis primary UM, which would
not be desirable in patient treatment. Again, this cannot simply be explained by the molecular structure
of this particular fucoidan, as we have shown before that this exact fucoidan reduced angiogenic
structures in RPE-endothelial cells co-cultures [33].
Fucoidan displayed a significant protective effect against H2O2-induced cell death in all tested
cell lines. Fucoidan has been reported to protect cells against oxidative stress [41,42]; however, to
the best of our knowledge, this has not been shown in cancer cells before. Indeed, fucoidan, when
given in addition with a chemotherapeutic, has been shown to increase oxidative stress in breast
cancer cell [43]. Antioxidants may enhance tumor progression [20] and oxidative stress may protect
from metastasis [21], so the protection of cancer cells against oxidative stress by fucoidan has to be
taken into consideration when discussing fucoidan-derived drugs as possible new cancer agents [14].
Our data showed that the protective effects of fucoidan are not mediated via a change in the Bcl-2/Bax
expression, or via the ERK1/2 or Akt pathway. Further research needs to be conducted in order to
decipher the protective pathways of these compounds.
Fucoidan is also under investigation to be used in combination with other chemotherapeutic
drugs in order to enhance their efficacy, as seen in e.g., melanoma [44] or breast cancer cells [43],
where pro-apoptotic or anti-proliferative effects of the chemotherapeutics are enhanced by fucoidan.
The results found in our study cannot be extrapolated towards combination treatments, however, the
effect of fucoidan in combination treatments is also cell type dependent and may reduce the efficacy of
the chemotherapeutic compound [45]. Moreover, it has been suggested that the apoptosis-enhancing
effects of combination therapies combining fucoidan and chemotherapy is mediated by oxidative
stress-enhancement by fucoidan [43], while our data show that fucoidan protects against oxidative
stress. Therefore, our data cannot give a prediction about potential combination therapies in UM, and
would strongly advise for caution in this area.
4. Conclusions
The data obtained in this study indicate that fucoidan is not suitable as a potential treatment
for UM.
5. Material and Methods
5.1. Cell Culture of Melanoma Cells
Five established human UM cell lines were used. The cell lines 92.1 [46] and Mel270 [47] originated
from primary UM, while all OMM cell lines are of metastatic origin; OMM2.5 and OMM2.3 from liver
metastases [47] and OMM1 from a sub-cutaneous metastasis [48]. Cell cultures were maintained in
RPMI (PAA Laboratories, Cölbe, Germany), supplemented with 10% fetal calf serum (FCS) (Linaris,
Dossenheim, Germany) and 1% penicillin/streptomycin (PAA). Medium was exchanged three times a
week and cells were passaged after reaching confluence.
5.2. Fucoidan
For the experiments, fucoidan from Sigma Aldrich (from Fucus vesiculosus, Sigma Aldrich,
Steinheim, Germany; #F5631, [O28K3779; CAS 9072-19-9]) was used.
5.3. Proliferation
To determine the influence of fucoidan on proliferation, a defined number (200,000 cells) of the
respective cell line was seeded on 12 well plates. Cells were stimulated with 100 µg/mL fucoidan for
up to three days. In addition, for the cell lines OMM1 and OMM2.3, a dose-response curve after 24 h
of incubation was determined, investigating 1 µg/mL, 10 µg/mL, 100 µg/mL and 1 mg/mL fucoidan.
After the indicated period of time, a WST-assay was conducted.
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5.4. WST-Assay
Treated cells as described above were treated with WST-1 reagent (Hoffmann-La Roche, Basel,
Switzerland) for 4 h at 37◦. The cells were rocked on a shaker for 2 min, the supernatant was collected,
and measured at 450 nm.
5.5. Scratch Assay
The scratch assay was conducted as previously described with modifications [33]. In brief, the
respective cell line was seeded in a 12-well-plate. Two wounds were scratched in the confluent cell
layer with a pipette tip and the cells were washed with PBS to remove detached cells. Microscopic
bright field pictures of three spots were taken (AxioCam, Zeiss, Jena, Germany). Fucoidan (100 µg/mL)
was added to the wells. After 90% wound closure of the control, another picture was taken. To analyse
the wound healing capability of the cells, application was conducted in duplicates and three pictures
per well were taken. The gap size of the wound was measured with AxioVision Rel.4.8. (Zeiss, Jena,
Germany), and the percentage of coverage of the wound was evaluated. Complete coverage was
defined as 100%.
5.6. VEGF-ELISA
The supernatant of cell cultures was collected after 100 µM fucoidan incubation for up to three
days. In addition, for the cell lines OMM1 and OMM2.3, a dose-response curve after 24 h of incubation
was determined, investigating 1 µg/mL, 10 µg/mL, 100 µg/mL and 1 mg/mL fucoidan. VEGF-content
was measured by VEGF-ELISA (R&D Systems, Wiesbaden, Germany), following the manufacturer’s
instructions. The range of detection of the ELISA was between 15 pg/mL and 1046 pg/mL. The amount
of VEGF secreted was normalized to cell number. Cell number was assessed with a trypan blue
exclusion assay.
5.7. Angiogenesis Assay
Angiogenesis was evaluated in a direct co-culture system of UM cells and outgrowth
endothelial cells.
The isolation of outgrowth endothelial cells from peripheral blood was conducted as described
previously [49,50]. In brief, these cells were isolated from buffy coats by isolation of blood
mononuclear cells. Mononuclear cells were seeded onto collagen coated 24-well plates in a density of
5 × 106 cells/well in EGM-2 (Lonza, Basel, Switzerland) with full supplements from the kit, 5% FCS,
and 1% penicillin/streptomycin. After one week, adherent cells were collected by trypsin and reseeded
on collagen coated 24-well plates in a density of 0.6 × 106 cells/well. After 2–3 weeks, colonies of
endothelial cells (OEC) were harvested and further expanded over several passages using EGM-2 in a
splitting ratio of 1:2.
Co-culture assays were performed for one primary (92.1) and one metastatic (OMM2.3) melanoma
cell line. For co-cultures 100,000 cells/cm2 were seeded into fibronectin coated thermanox coverslips
in 24 well plates in their respective cell culture medium. On the next day outgrowth endothelial
cells (OEC) were added to the cultures in a density of 100,000 cells/cm2 to the respective uveal
melanoma cell line and co-cultures were further maintained for seven days in EGM-2 treated with
100 µg/mL fucoidan, respectively, or left untreated in control groups. After seven days, co-cultures
were fixed with 4% paraformaldehyde and outgrowth endothelial cells were immunostained for the
endothelial marker CD31. All cells are counterstained by Hoechst and pictures were taken with a
confocal laser scanning microscope (Zeiss LSM 510 Meta, Jena, Germany). Angiogenesis was evaluated
in comparison to untreated controls. For each group, at least three pictures were taken from two
technical replicates. These experiments and the picture analysis were performed with endothelial cells
from three different donors.
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5.8. Image Analysis
The microscopic images were analyzed using the image processing program ImageJ Vers. 1.47
and GIMP 2.8. The analysis of angiogenic structures was conducted as previously described [51].
In brief, tube-like structures were extracted from the background by automatic segmentation after
background correction. The binaries of the tube-like structures were further processed, including a
final manual correction. The resulting binaries were analyzed for the area and the length of tubular
structures. Additionally, the total area of fluorescence was assessed after automatic segmentation.
5.9. Cytotoxicity
Cells were plated on 24-well plates. H2O2 (Sigma-Aldrich, Munich, Germany) was applied in
order to induce oxidative stress mediated cytotoxicity. We have previously shown that uveal melanoma
cell lines show a cell-line specific susceptibility to oxidative stress [32]. Cytotoxicity was induced by
applying H2O2 in the respective concentration (92.1:250 µM, Mel270 and OMM1: 500 µM, OMM2.3
and OMM2.5:1000 µM). In order to evaluate a potential protective effect of fucoidan, confluent cells
were treated 30 min prior to oxidative insult with 100 µg/mL fucoidan. Cell viability was assessed
after 24 h of stimulation with a WST assay.
5.10. Whole Cell Lysate
After treatment of cells as indicated, whole cell lysates were prepared in an NP-40 buffer as
described previously [33]. In brief, cells were washed with PBS and NP-40 buffer (1% Nonidet®
P40 Substitute, 150 mM NaCl, 50 mM Tris, pH 8.0) was added. The lysates were kept on ice for
at least 30 min. Lysates were centrifuged at 13,000 rpm for 15 min and the supernatant harvested.
The protein concentration of the supernatant was determined by a BioRad protein assay (BioRad,
München, Germany) with bovine serum albumin (Fluka, Buchs, Switzerland) used as standard.
5.11. Western Blot
Western blot was conducted as described previously with modifications [52]. In brief, proteins
were separated in an SDS-PAGE, using 12% acrylamide gels. Gels were blotted on PVDF-membranes
(Carl Roth GmbH, Karlsruhe, Germany) and then blocked in 4% skim milk in Tris buffered saline with
0.1% Tween for 1 h at room temperature. The blot was treated with the first antibodies, beta-actin (#4967,
1:1000), Akt (#9272, 1:1000), ERK1/2 (#9102, 1:1000), p-ERK1/2 (#9101, 1:1000) (all Cell-Signaling
Technologies, CST, Denver, CO, USA; all rabbit), Bax (sc-20067, 1:1000) or Bcl-2 (sc-509, 1:1000) (all
Santa Cruz, Heidelberg, Germany, all mouse), respectively, in 2% skim milk in Tris buffered saline with
0.1% Tween overnight at 4 ◦C. After washing the blot, it was incubated with appropriate secondary
antibody (anti-rabbit (#7074) or anti-mouse (#7076) IgG, HRP-linked antibody (all Cell-Signaling)) in
2% skim milk in Tris-buffered saline with 0.1% Tween (Merck, Darmstadt, Germany). Following the
final wash, the blot was incubated with Immobilon chemiluminscence reagent (Merck), and the signal
was detected with MF-ChemiBis 1.6 (Biostep, Jahnsdorf, Germany). The density of the bands was
evaluated using Total lab software (Biostep) and the signal was normalized for ß-actin.
5.12. Statistics
Statistical analysis was performed with MS-Excel. Means± standard deviation (sd) was calculated
for at least three independent sets of experiments. Significant differences between means were
calculated by t-test. A p-value of 0.05 or less was considered significant.
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